Afasevikumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAfasevikumab

Drug Alias NameRO-5553110MCAF-5352ARG-7624NI-1401

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionInterleukin-17 inhibitors

TargetsInterleukin-17

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovimmune Sa

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesGenentech Inc

Active IndicationsN/A

Inactive IndicationsN/A

ATC CodeN/A